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SHORT REPORT
Abnormal pontine activation in pathological laughing as
shown by functional magnetic resonance imaging
H Kosaka, N Omata, M Omori, T Shimoyama, T Murata, K Kashikura, T Takahashi, J Murayama,
Y Yonekura, Y Wada
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
J Neurol Neurosurg Psychiatry 2006;77:1376–1380. doi: 10.1136/jnnp.2005.073288
To explore the aetiology of pathological laughing, a 65-year-
old woman with pathological laughing was examined by 3-T
functional magnetic resonance imaging (fMRI) before and
after treatment with drugs. Here, we report that the patient
consistently showed exaggerated pontine activation during
the performance of three tasks before treatment, whereas
abnormal pontine activation was no longer found after
successful treatment with the selective serotonin reuptake
inhibitor, paroxetine. Our findings in this first fMRI study of
pathological laughing suggest that serotonergic replacement
decreases the aberrant activity in a circuit that involves the
pons.
P
athological laughing and crying (PLC) is defined as a
sudden loss of emotional control, occurs in response to
non-specific stimuli, and lacks an associative and
matching mood state.1 Previous studies have shown that
PLC appears in association with various brain disorders such
as pseudo-bulbar palsy, subcortical and brain stem infarc-
tions and injury, tumours in the cerebellopontine region,
multiple sclerosis, and amyotrophic lateral sclerosis.1–8
However, the pathogenesis of PLC remains unclear and to
date there have not been any functional neuroimaging
studies of PLC. We conducted functional magnetic resonance
imaging (fMRI) using a 3-T magnetic resonance scanner to
investigate the brain function of a patient with pathological
laughing before and after treatment with drugs, and
compared these findings with fMRI data from normal
volunteers.
CASE REPORT
A 65-year-old right-handed woman with pathological laugh-
ing developed episodes of inappropriate and uncontrollable
laughing at the age of 62 years. The laughing episodes were
not accompanied by a sense of joy or any other pleasurable
feeling. These spells occurred even in stressful situations such
as when she was reproved by her husband. As her episodes of
uncontrolled laughing began to occur almost every day, she
was admitted to our hospital.
She had no history of neurological or psychiatric disease,
and there was no sign of drug or alcohol abuse. Motor
strength and stretch reflexes were normal. On testing of all
sensory modalities, no apparent abnormalities were observed.
The status of all cranial nerve nuclei (including the facial
nucleus) was also normal. Scores on Hamilton rating scale
for both anxiety (5 points) and depression (3 points) were
low, and there were no apparent psychiatric diseases such as
anxiety disorders or depression. Brain magnetic resonance
imaging, including fast fluid-attenuated inversion-recovery
and diffusion-weighted imaging, showed no apparent abnor-
mal findings such as tumour, haemorrhage, infarction or
severe cortical atrophy. 99mTc-ECD SPECT and electroence-
phalogram were also unremarkable. Mini Mental State
Examination showed a full score of 30 points. We could not
detect any apparent organic brain disorders such as epilepsy,
infarction or dementia.
On the basis of reports of the effectiveness of the selective
serotonin reuptake inhibitor (SSRI) on PLC,5 7 9 10 treatment
with paroxetine was started at 10 mg daily 2 weeks after
hospitalisation. Paroxetine 10 mg/day led to a gradual
reduction in the number of laughing episodes at 2 weeks,
which eventually disappeared within 6 weeks after an
increase to 20 mg/day.
METHODS
We conducted fMRI using T2*-weighted, gradient echo, echo
planar imaging (EPI) sequences with a 3-T magnetic
resonance scanner (Signa Horizon; General Electric Medical
Systems, Milwaukee, Wisconsin, USA). Three types of
experimental tasks were performed to establish responses
to non-specific stimuli. The protocol was approved by the
Ethical Committee of Fukui Medical University (Fukui,
Japan), and the patient gave written informed consent for
the study.
During scanning, stimuli were projected onto a semitran-
sparent screen using an liquid crystal display projector
connected to a personal computer that generated the stimuli.
The subject saw the stimuli through a tilted mirror attached
to the head coil of the scanner. The subject’s head was
immobilised with comfortable foam and taped to the head
folder to prevent motion.
fMRI analysis was performed based on a block design,
alternating control and task, as previously reported.11 (A)
During the sex discrimination task, the patient was
instructed to judge the sex of face pairs, and to discriminate
the size of two rectangles during the control condition
(control/task block = 32/96 s, repetition time or echo
time(TR/TE) = 4000/30 ms, flip angle = 90 ,˚ 64664 matrix
and 44 slices, 3 mm slice thickness, 136 images in total). (B)
During the semantic decision task, she was told to push the
button if the presented word was an animal name, and to
push the button if the presented cross-character disappeared
during the control condition (control/task block = 27/27 s,
TR/TE = 3000/30 ms, flip angle = 90 ,˚ 64664 matrix and 36
slices, 4 mm slice thickness, 126 images in total). (C) During
the finger-tapping task, she was instructed to alternately
press the buttons with her right index and ring fingers at
about 1 Hz, and she remained at rest during the control
condition (control/task block = 28/28 s, TR/TE = 4000/30 ms,
flip angle = 90 ,˚ 64664 matrix and 44 slices, 3 mm slice
thickness, 112 images in total). The patient experienced
Abbreviations: EPI, echo planar imaging; fMRI, functional magnetic
resonance imaging; PLC, pathological laughing and crying; SSRI,
selective serotonin reuptake inhibitor; TR/TE, repetition time or echo time
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laughing episodes only during the scanning of the sex
discrimination task before treatment. Each task performance
was over 90% correct. Imaging processing and statistical
analyses were performed using Statistical Parametric
Mapping 99 software (Wellcome Department of Cognitive
Neurology, University College London, London, UK). To
correct for dislocations caused by head motion, all EPI images
were realigned. These images were then normalised to the
Montreal Neurological Institute atlas12 using the parameter
obtained from the normalisation process of the anatomical
image that was coregistered to the first EPI image before-
hand. The images were smoothed by using an 8-mm gaussian
kernel. The statistical threshold was set at p,0.05 (corrected)
for each voxel (fig 1). Then, we compared with data of control
subjects obtained from our previous studies.13
RESULTS
During the sex discrimination task, as compared with the
control condition (fig 1A, table 1), the patient showed broad
and significant activation in the pons and cerebellum before
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Figure 1 Functional magnetic resonance imaging findings of normal volunteers and the patient with pathological laughing before and after treatment.
(A) During the sex discrimination task (12 normal volunteers and the patient). (B) During the semantic decision task (11 normal volunteers and the
patient). (C) During the finger-tapping task (six normal volunteers and the patient). The figures depict brain areas showing significant activation during
each task compared with each control condition in normal volunteers (left column) and the patient with pathological laughing before (middle column)
and after (right column) treatment with paroxetine. The task-related increase in magnetic resonance signal was superimposed on the mean T2-weighted
image (control subjects, left column) and the patient’s own normalised T2-weighted image (middle and right column; p,0.05, corrected). Abnormal
pontine activation during the experimental tasks was shown only in the patient before treatment. The blue lines indicate the pons, at Talairach
coordinates [0, 226, 230].
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Table 1 Brain areas of significant activation during the sex discrimination, semantic
decision and finger-tapping tasks in normal volunteers and the patient with pathological
laughing before and after treatment
Normal group
The patient with pathological laughing
Without paroxetine With paroxetine
(A) The sex discrimination task (12 normal volunteers and the patient)
Rt. Fusiform gyrus Pons Lt. fusiform gyrus
(40, 278, 216) (6, 236, 222) (238, 242, 228)
(Z = 5.55) (Z = 5.27) (Z = 7.46)
Lt. Fusiform gyrus Lt. fusiform gyrus Lt. inferior temporal gyrus
(238, 276, 216) (238, 242, 228) (240, 266, 22)
(Z = 4.85) (Z = 8.00) (Z = 4.38)
Rt. amygdala Lt. amygdala
(16, 26, 218) (222, 210, 214)
(Z = 4.33) (Z = 5.78)
Lt. amygdala Lt. inferior temporal gyrus
(216, 26, 218) (240, 268, 2)
(Z = 4.47) (Z = 5.15)
Rt. inferiot frontal gyrus Rt. cerebellum (MCP)
(46, 14, 26) (12, 240, 230)
(Z = 5.57) (Z = 4.63)
Lt. middle frontal gyrus Lt. cerebellum (MCP)
(236, 8, 34) (28, 242, 238)
(Z = 4.20) (Z = 4.40)
Rt. hippocampus
(34, 216, 216)
(Z = 4.05)
Rt. lingual gyrus
(22, 270, 2)
(Z = 4.17)
(B) The semantic decision task (11 normal volunteers and the patient)
Rt. lingual gyrus Pons Rt. lingual gyrus
(32, 280, 220) (2, 234, 232) (22, 272, 218)
(Z = 5.76) (Z = 4.35) (Z = 7.37)
Lt. lingual gyrus Rt. lingual gyrus Lt. lingual gyrus
(210, 290, 214) (18, 290, 210) (222, 282, 222)
(Z = 7.62) (Z = 7.35) (Z = 8.00)
Lt. Fusiform gyrus Lt. lingual gyrus Rt. superior parietal lobe
(238, 274, 216) (216, 286, 214) (28, 274, 22)
(Z = 7.72) (Z = 8.00) (Z = 7.04)
Lt. inferior frontal gyrus Rt. superior parietal lobe Lt. superior parietal lobe
(252, 28, 32) (28, 274, 18) (220, 268, 38)
(Z = 5.72) (Z = 4.95) (Z = 7.82)
Rt. postcentral gyrus Lt. superior parietal lobe Rt. inferior temporal gyrus
(52, 214, 40) (222, 266, 26) (54, 240, 214)
(Z = 4.75) (Z = 6.05) (Z = 4.54)
Lt. postcentral gyrus Lt. inferior temporal gyrus Lt. inferior temporal gyrus
(244, 228, 58) (256, 242, 214) (254, 244, 222)
(Z = 5.36) (Z = 6.09) (Z = 7.38)
Rt. middle frontal gyrus Lt. middle temporal gyrus Rt. middle temporal gyrus
(42, 10, 52) (244, 236, 24) (44, 228, 210)
(Z = 4.56) (Z = 7.01) (Z = 4.45)
Rt. Superior parietal lobe Rt. inferior frontal gyrus Lt. middle temporal gyrus
(14, 254, 54) (26, 32, 218) (244, 236, 28)
(Z = 4.53) (Z = 3.72) (Z = 7.15)
Rt. cerebellum Lt. middle frontal gyrus Rt. inferior frontal gyrus
(20, 272, 218) (244, 6, 50) (38, 212, 30)
(Z = 3.90) (Z = 7.09) (Z = 4.30)
Lt. inferior frontal gyrus Lt. middle frontal gyrus
(226, 30, 214) (226, 0, 28)
(Z = 5.52) (Z = 8.00)
Lt. supplementary motor area Rt. cerebellum
(28, 10, 60) (24, 256, 232)
(Z = 5.88) (Z = 8.00)
Rt. precentral gyrus Lt. cerebellum
(60, 24, 32) (224, 252, 234)
(Z = 5.79) (Z = 6.36)
Rt. cerebellum
(22, 272, 240)
(Z = 5.90)
(C) The finger-tapping task (six normal volunteers and the patient)
Lt. precentral gyrus Pons Rt. precentral gyrus
(224, 230, 66) (26, 236, 238) (62, 2, 24)
(Z = 4.59) (Z = 5.22) (Z = 5.70)
Lt. Superior temporal gyrus Rt. precentral gyrus Lt. precentral gyrus
(252, 8, 10) (60, 24, 28) (230, 210, 64)
(Z = 3.62) (Z = 5.25) (Z = 6.88)
Lt. supplementary motor area Lt. precentral gyrus Lt. supplementary motor area
(26, 26, 68) (230, 224, 42) (28, 2 84)
(Z = 4.22) (Z = 6.94) (Z = 5.66)
Rt. cerebellum Lt. inferior temporal gyrus Lt. anterior cingulate
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treatment with paroxetine, which was not observed in any of
the 12 normal volunteers. During the semantic decision task
(fig 1B, table 1), significant pontine activation was also
observed only in the patient, although the bilateral pre-
frontal, parietal and occipital cortices and cerebellum were
activated in the patient and the 11 normal volunteers. During
the finger-tapping task (fig 1C, table 1), the pons was
considerablly activated only in the patient, although sig-
nificant activation was found in the motor and temporal
cortices, supplementary motor area and cerebellum in the
patient and the six normal volunteers. None of the normal
control subjects showed significant pontine response to any
experimental task in intra-subject analysis. Although the
patient experienced laughing episodes during scanning, the
magnitude of head movement during all tasks was,0.6 mm.
The fMRI was also examined after the complete disap-
pearance of the patient’s symptoms (ie, after 8 weeks of
treatment with drugs). This analysis showed that abnormal
pontine activation during the performance of each task was
no longer found after successful treatment with paroxetine.
Although significant cerebellum activation seen before
treatment with paroxetine also disappeared during the sex
discrimination task, it persisted during the other two tasks
after treatment (fig 1, table 1).
DISCUSSION
This is the first fMRI study of pathological laughing in which
a patient consistently showed pontine hyperactivity during
different types of tasks.
There are two major hypotheses regarding PLC. One is that
lesions of the voluntary paths from the motor cortex to the
brain stem laughing and crying centre, which controls facial
and respiratory muscles, can cause involuntarily initiated
laughing and crying.2 The other is that dysfunction of the
cerebro-ponto-cerebellar pathways causes inappropriate
laughing or crying behaviour because the cerebellum fails
to adjust the execution of laughing or crying to the cognitive
and situational context of a potential stimulus.10 In the
present study, three types of fMRI experiment tasks, facial
recognition, semantic decision and motor function, were
used to establish the response to non-specific stimuli. The
patient showed consistent abnormal pontine activation not
seen in any control subject during the performance of all
tasks before treatment, and when the laughing episodes
disappeared after treatment with paroxetine, the exaggerated
pontine activation was normalised. Thus, it was suggested
that the pons might be a part of the aetiological focus for
pathological laughing. In addition to the pons, significant
cerebellum activation was also found before treatment in our
patient. Although it was seen to some extent even in the
control subjects and activation change in the cerebellum after
treatment was not as dramatic as that in the pons, abnormal
cerebellar function might also be related to the emergence of
PLC in accord with the second hypothesis.
There is also increasing evidence that SSRIs are effective
against PLC.5 7 9 10 Our fMRI results, in which the abnormal
pontine activity disappeared with clinical improvement after
treatment with paroxetine, also suggested some SSRI efficacy
in PLC. Although the response to SSRI in our patient was
relatively slow compared with other reports in which rapid
improvement was seen within 1 week,14–16 a favourable
response was obtained in 2 weeks in our patient.
Whereas pathological laughing was present in only one
task (sex discrimination), abnormal brain stem activation
was present for all task comparisons. One of the possible
explanations for this discrepancy was that the pons, or a
putative pathway for PLC associated with the pons, might
always remain functionally abnormal during the disease
episodes, and then clinical episodes of PLC would occur
episodically in response to non-specific triggering until
successful treatment; however, it remains unclear how the
threshold for triggering these attacks is set or modulated.
As there are also some fMRI studies that reported brain
stem activation associated with the pons during auditory
stimulation or sensory stimulation in response to faces,17–19 it
is considered that pontine hyperactivity in the present
findings was not likely to be caused by mere motion artefacts.
Further, the patient experienced only one laughing episode
during the task, and this episode was transient and lasted for
less than a minute without vocalisation. The subject’s head
movement was very slight (ie, ,0.6 mm), but even if pontine
hyperactivity was an artefact due to gross head motion,
breathing motion or heart beat, it is hard to consider that
these elements happened only during the task, and not
during the control periods. Although further studies with a
large number of patients and age-matched control subjects
are needed, the present findings contribute to our under-
standing of the neuronal mechanism responsible for PLC and
suggest treatment strategies for this condition.
Normal group
The patient with pathological laughing
Without paroxetine With paroxetine
(22, 250, 220) (240, 214, 226) (26, 212 50)
(Z = 3.98) (Z = 5.92) (Z = 5.22)
Lt. superior temporal gyrus Lt. inferior frontal gyrus
(258, 226, 22) (248, 10, 28)
(Z = 5.36) (Z = 5.01)
Rt. lingual gyrus Rt. cerebellum
(18, 288, 26) (28, 250, 228)
(Z = 5.93) (Z = 6.40)
Rt. superior frontal gyrus
(20, 66 26)
(Z = 5.04)
Rt. superior occipital gyrus
(36, 274, 10)
(Z = 4.95)
Rt. cerebellum
(20, 256, 230)
(Z = 7.44)
Lt. cerebellum
(220, 252, 232)
(Z = 8.00)
MCP, middle cerebellar peduncle; Rt., right; Lt, left.
Table 1 Continued
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